Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41467-021-24265-8 http://scihub22266oqcxt.onion/10.1038/s41467-021-24265-8 34230477!8260641!34230477     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Commun 2021 ; 12 (1): 4015 Nephropedia Template TP {{tp|p=34230477|t=2021. Lack of consideration of sex and gender in COVID-19 clinical studies |pdf=|usr=}}{{34230477}} gab.com Text Lack of consideration of sex and gender in COVID-19 clinical studies JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=34230477 #FOAvip Sex and gender differences impact the incidence of SARS-CoV-2 infection and COVID-19 mortality. Furthermore, sex differences influence the frequency and severity of pharmacological side effects. A large number of clinical trials to develop new therapeutic approaches and vaccines for COVID-19 are ongoing. We investigated the inclusion of sex and/or gender in COVID-19 studies on ClinicalTrials.gov, collecting data for the period January 1, 2020 to January 26, 2021. Here, we show that of the 4,420 registered SARS-CoV-2/COVID-19 studies, 935 (21.2%) address sex/gender solely in the context of recruitment, 237 (5.4%) plan sex-matched or representative samples or emphasized sex/gender reporting, and only 178 (4%) explicitly report a plan to include sex/gender as an analytical variable. Just eight (17.8%) of the 45 COVID-19 related clinical trials published in scientific journals until December 15, 2020 report sex-disaggregated results or subgroup analyses. Twit Text FOAVip Lack of consideration of sex and gender in COVID-19 clinical studies ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=34230477 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34230477 #FOAvip English Wikipedia <ref>{{Cite pmid|34230477}}</ref> Lack of consideration of sex and gender in COVID-19 clinical studies #MMPMID34230477 Brady E; Nielsen MW; Andersen JP; Oertelt-Prigione S Nat Commun 2021[Jul]; 12 (1): 4015 PMID34230477show ga Sex and gender differences impact the incidence of SARS-CoV-2 infection and COVID-19 mortality. Furthermore, sex differences influence the frequency and severity of pharmacological side effects. A large number of clinical trials to develop new therapeutic approaches and vaccines for COVID-19 are ongoing. We investigated the inclusion of sex and/or gender in COVID-19 studies on ClinicalTrials.gov, collecting data for the period January 1, 2020 to January 26, 2021. Here, we show that of the 4,420 registered SARS-CoV-2/COVID-19 studies, 935 (21.2%) address sex/gender solely in the context of recruitment, 237 (5.4%) plan sex-matched or representative samples or emphasized sex/gender reporting, and only 178 (4%) explicitly report a plan to include sex/gender as an analytical variable. Just eight (17.8%) of the 45 COVID-19 related clinical trials published in scientific journals until December 15, 2020 report sex-disaggregated results or subgroup analyses. |COVID-19/epidemiology/*therapy[MESH] |Clinical Studies as Topic/*statistics & numerical data[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Patient Selection[MESH] |SARS-CoV-2[MESH]Lack of consideration of sex and gender in COVID-19 clinical studies (epmc).pdf DeepDyve Pubget Overpricing